Hui‐Zi Chen

3.6k total citations · 3 hit papers
25 papers, 2.6k citations indexed

About

Hui‐Zi Chen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hui‐Zi Chen has authored 25 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Hui‐Zi Chen's work include Cancer Genomics and Diagnostics (7 papers), Fibroblast Growth Factor Research (5 papers) and Genetic factors in colorectal cancer (4 papers). Hui‐Zi Chen is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Fibroblast Growth Factor Research (5 papers) and Genetic factors in colorectal cancer (4 papers). Hui‐Zi Chen collaborates with scholars based in United States, Italy and Malaysia. Hui‐Zi Chen's co-authors include Gustavo Leone, Shih‐Yin Tsai, Sameek Roychowdhury, Melanie A. Krook, Julie W. Reeser, Russell Bonneville, Michele R. Wing, Jharna Miya, Lianbo Yu and Esko A. Kautto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature reviews. Cancer.

In The Last Decade

Hui‐Zi Chen

25 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Landscape of Microsatellite Instability Across 39 Cancer Types

2017 1.0k citations Russell Bonneville, Melanie A. Krook et al. profile →
Emerging roles of E2Fs in cancer: an exit from cell cycle control

2009 778 citations Hui‐Zi Chen, Shih‐Yin Tsai et al. Nature reviews. Cancer profile →
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

2020 213 citations Melanie A. Krook, Julie W. Reeser et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hui‐Zi Chen United States	12	1.4k	1.1k	774	656	404	25	2.6k
In‐Gu Do South Korea	31	1.1k 0.8×	1.0k 0.9×	516 0.7×	691 1.1×	424 1.0×	97	2.5k
Hee Eun Lee South Korea	29	1.0k 0.7×	1.3k 1.2×	680 0.9×	707 1.1×	338 0.8×	86	2.7k
Gregor Krings United States	27	1.2k 0.9×	825 0.7×	813 1.1×	438 0.7×	394 1.0×	62	2.8k
Vassiliki Kotoula Greece	27	1.2k 0.9×	1.2k 1.0×	539 0.7×	419 0.6×	299 0.7×	125	2.6k
Yoshihiko Kitajima Japan	29	1.6k 1.1×	956 0.9×	836 1.1×	413 0.6×	254 0.6×	85	2.7k
Yutaka Hatanaka Japan	27	712 0.5×	1.2k 1.1×	533 0.7×	653 1.0×	232 0.6×	143	2.2k
Gregory M. Coté United States	35	1.3k 0.9×	1.3k 1.1×	485 0.6×	1.4k 2.1×	411 1.0×	151	3.4k
Björn Nodin Sweden	32	1.0k 0.7×	1.5k 1.3×	594 0.8×	579 0.9×	488 1.2×	118	2.8k
Simone Reu Germany	20	826 0.6×	1.2k 1.1×	394 0.5×	596 0.9×	254 0.6×	53	2.2k
Julie Izzo United States	31	1.5k 1.1×	1.3k 1.2×	565 0.7×	680 1.0×	231 0.6×	57	2.9k

Countries citing papers authored by Hui‐Zi Chen

Since Specialization

Citations

This map shows the geographic impact of Hui‐Zi Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui‐Zi Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui‐Zi Chen more than expected).

Fields of papers citing papers by Hui‐Zi Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui‐Zi Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui‐Zi Chen. The network helps show where Hui‐Zi Chen may publish in the future.

Co-authorship network of co-authors of Hui‐Zi Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Hui‐Zi Chen. A scholar is included among the top collaborators of Hui‐Zi Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui‐Zi Chen. Hui‐Zi Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Hui‐Zi, Na Hyun Kim, Daisuke Nishizaki, et al.. (2025). PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome. npj Genomic Medicine. 10(1). 21–21. 4 indexed citations

Subbiah, Vivek, Giuseppe Curigliano, Jason K. Sicklick, et al.. (2025). Cancer treatment paradigms in the precision medicine era. Nature Medicine. 31(11). 3609–3611. 3 indexed citations

Karan, Dev, Seema Dubey, Sumedha Gunewardena, et al.. (2024). Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8‐DNA interactions and effectively inhibits prostate tumor growth in mice. Molecular Oncology. 18(8). 1966–1979. 2 indexed citations

Shreenivas, Aditya, Filip Jankú, Mohamed A. Gouda, et al.. (2023). ALK fusions in the pan-cancer setting: another tumor-agnostic target?. npj Precision Oncology. 7(1). 101–101. 44 indexed citations

Wang, Fang, et al.. (2021). Effectiveness of a novel 1% glucose isotonic electrolyte solution for intraoperative fluid therapy in children: a randomized controlled trial. Journal of International Medical Research. 49(11). 3619116552–3619116552. 2 indexed citations

Chen, Hui‐Zi, Russell Bonneville, Julie W. Reeser, et al.. (2021). Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. JTO Clinical and Research Reports. 2(4). 100164–100164. 13 indexed citations

Krook, Melanie A., Max Wilberding, Kelly M. Bailey, et al.. (2020). Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Molecular Cancer Therapeutics. 19(3). 847–857. 106 indexed citations

Bonneville, Russell, Michele R. Wing, Melanie A. Krook, et al.. (2020). Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing. Molecular Cancer Research. 19(3). 465–474. 7 indexed citations

Krook, Melanie A., Julie W. Reeser, Gabrielle Ernst, et al.. (2020). Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. British Journal of Cancer. 124(5). 880–892. 213 indexed citations breakdown →

10.

Krook, Melanie A., Hui‐Zi Chen, Julie W. Reeser, et al.. (2019). Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 22(4). 624–632. 5 indexed citations

11.

Bonneville, Russell, Melanie A. Krook, Hui‐Zi Chen, et al.. (2019). Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. Methods in molecular biology. 2055. 119–132. 53 indexed citations

12.

Krook, Melanie A., Russell Bonneville, Hui‐Zi Chen, et al.. (2019). Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Molecular Case Studies. 5(4). a004002–a004002. 63 indexed citations

13.

Krook, Melanie A., Max Wilberding, Hui‐Zi Chen, et al.. (2019). Abstract 335: Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. 335–335. 1 indexed citations

14.

Krook, Melanie A., et al.. (2018). Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity. Trends in cancer. 5(1). 1–5. 11 indexed citations

15.

Chen, Hui‐Zi, Russell Bonneville, & Sameek Roychowdhury. (2018). Implementing precision cancer medicine in the genomic era. Seminars in Cancer Biology. 55. 16–27. 24 indexed citations

16.

Carr, David R., Llana Pootrakul, Hui‐Zi Chen, & Catherine Chung. (2018). Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor. JAMA Dermatology. 155(1). 122–122. 15 indexed citations

17.

Wang, Hui, Shan K. Naidu, Ravi Rajmohan, et al.. (2010). Allele-specific tumor spectrum in Pten knockin mice. Proceedings of the National Academy of Sciences. 107(11). 5142–5147. 54 indexed citations

18.

Chen, Hui‐Zi, Shih‐Yin Tsai, & Gustavo Leone. (2009). Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nature reviews. Cancer. 9(11). 785–797. 778 indexed citations breakdown →

19.

Zhang, Xiaolan, Xilin Chen, Huijuan Song, Hui‐Zi Chen, & Brad H. Rovin. (2005). Activation of the Nrf2/antioxidant response pathway increases IL-8 expression. European Journal of Immunology. 35(11). 3258–3267. 83 indexed citations

20.

Chen, Hui‐Zi. (2001). Detection of Mucin Gene Expression in Normal Rat Middle Ear Mucosa by Reverse Transcriptase-Polymerase Chain Reaction. Acta Oto-Laryngologica. 121(1). 45–51. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact